Base de dados : MEDLINE
Pesquisa : D02.145.074.722.822 [Categoria DeCS]
Referências encontradas : 1967 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 197 ir para página                         

  1 / 1967 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215216
[Au] Autor:Garrison SR; Allan GM
[Ad] Endereço:University of Alberta, Edmonton, AB, Canada
[Ti] Título:Tiotropium in Early-Stage COPD.
[So] Source:N Engl J Med;377(23):2293, 2017 12 07.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Derivados da Escopolamina
Brometo de Tiotrópio
[Mh] Termos MeSH secundário: Broncodilatadores
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Scopolamine Derivatives); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1713253


  2 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215215
[Au] Autor:Kerwin E
[Ad] Endereço:Clinical Research Institute, Medford, OR ekerwin@criresearch.com
[Ti] Título:Tiotropium in Early-Stage COPD.
[So] Source:N Engl J Med;377(23):2292-3, 2017 12 07.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Derivados da Escopolamina
Brometo de Tiotrópio
[Mh] Termos MeSH secundário: Broncodilatadores
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Scopolamine Derivatives); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1713253


  3 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215214
[Au] Autor:Qian G; Ying F; Li G
[Ad] Endereço:Ningbo First Hospital, Ningbo, China
[Ti] Título:Tiotropium in Early-Stage COPD.
[So] Source:N Engl J Med;377(23):2292, 2017 12 07.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Derivados da Escopolamina
Brometo de Tiotrópio
[Mh] Termos MeSH secundário: Broncodilatadores
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Scopolamine Derivatives); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1713253


  4 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29211676
[Au] Autor:Ran P; Zhou Y; Guan WJ
[Ad] Endereço:Guangzhou Medical University, Guangzhou, China
[Ti] Título:Tiotropium in Early-Stage COPD.
[So] Source:N Engl J Med;377(23):2293-2294, 2017 12 07.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Derivados da Escopolamina
Brometo de Tiotrópio
[Mh] Termos MeSH secundário: Broncodilatadores
Seres Humanos
Doença Pulmonar Obstrutiva Crônica
Resultado do Tratamento
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Scopolamine Derivatives); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1713253


  5 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28387891
[Au] Autor:Chi YL; Li ZS; Lin CS; Wang Q; Zhou YK
[Ad] Endereço:Department of Anesthesiology, Department of General Surgery; The Affiliated Hospital of Shandong Traditional Chinese Medicine University, Jinan City, Shandong Province, China. 15553156588@163.com.
[Ti] Título:Evaluation of the postoperative cognitive dysfunction in elderly patients with general anesthesia.
[So] Source:Eur Rev Med Pharmacol Sci;21(6):1346-1354, 2017 Mar.
[Is] ISSN:2284-0729
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The present study is aimed to study the neuron-specific enolase (NSE) and S100b proteins in the evaluation of postoperative cognitive dysfunction in elderly patients with general anesthesia. PATIENTS AND METHODS: A total of 142 aged patients, who were treated with transurethral resection of the prostate (TURP) surgery under general anesthesia with propofol from June 2014 to December 2015, were randomly divided into two groups. The experiment group was given scopolamine butylbromide by intramuscular injection before the operation, while the control group had no preoperative intramuscular injection. The propofol was used for maintenance during the operation. The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scales were adopted for testing the patients on preoperative day 1, postoperative day 2 and postoperative day 9. After the surgery, there were 4 cases of postoperative cognitive dysfunction (POCD) patients in experiment group, while 21 cases of POCD patients in control group. While the 142 healthy adult volunteers, who were admitted to physical examination center of our hospital in the corresponding period, were selected as healthy controls. The expression levels of S100b and NSE of patients, as well as healthy controls, were detected by ELISA. RESULTS: In POCD patients, serum S100b and NSE levels were evidently higher than those of patients without POCD and healthy control group (p < 0.05). S100b and NSE levels of POCD patients in experiment group were significantly lower than those of control group (p < 0.05). Serum S100b and NSE levels are higher, the longer duration of POCD is, as the correlation coefficient rs = -0.1342, -1.6644, p < 0.05. CONCLUSIONS: The expression levels of S100b protein and plasma NSE in the serum of POCD patients increased, which indicated the severity of the disease. The preoperative intramuscular injection of scopolamine butylbromide has important clinical significance for the prevention of POCD.
[Mh] Termos MeSH primário: Anestesia Geral/efeitos adversos
Disfunção Cognitiva/induzido quimicamente
Complicações Pós-Operatórias/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso
Anestésicos Intravenosos/administração & dosagem
Disfunção Cognitiva/sangue
Seres Humanos
Hidrocarbonetos Bromados/administração & dosagem
Injeções Intramusculares
Masculino
Meia-Idade
Testes Neuropsicológicos
Fosfopiruvato Hidratase/sangue
Complicações Pós-Operatórias/sangue
Propofol/administração & dosagem
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
Derivados da Escopolamina/administração & dosagem
Ressecção Transuretral da Próstata
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (Hydrocarbons, Brominated); 0 (S100 Calcium Binding Protein beta Subunit); 0 (S100B protein, human); 0 (Scopolamine Derivatives); EC 4.2.1.11 (Phosphopyruvate Hydratase); SAV6Y78U3D (butyl bromide); YI7VU623SF (Propofol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE


  6 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28076656
[Au] Autor:Kirkland SW; Vandenberghe C; Voaklander B; Nikel T; Campbell S; Rowe BH
[Ad] Endereço:Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada.
[Ti] Título:Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma.
[So] Source:Cochrane Database Syst Rev;1:CD001284, 2017 01 11.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Inhaled short-acting anticholinergics (SAAC) and short-acting beta2-agonists (SABA) are effective therapies for adult patients with acute asthma who present to the emergency department (ED). It is unclear, however, whether the combination of SAAC and SABA treatment is more effective in reducing hospitalisations compared to treatment with SABA alone. OBJECTIVES: To conduct an up-to-date systematic search and meta-analysis on the effectiveness of combined inhaled therapy (SAAC + SABA agents) vs. SABA alone to reduce hospitalisations in adult patients presenting to the ED with an exacerbation of asthma. SEARCH METHODS: We searched MEDLINE, Embase, CINAHL, SCOPUS, LILACS, ProQuest Dissertations & Theses Global and evidence-based medicine (EBM) databases using controlled vocabulary, natural language terms, and a variety of specific and general terms for inhaled SAAC and SABA drugs. The search spanned from 1946 to July 2015. The Cochrane Airways Group provided search results from the Cochrane Airways Group Register of Trials which was most recently conducted in July 2016. An extensive search of the grey literature was completed to identify any other potentially relevant studies. SELECTION CRITERIA: Included studies were randomised or controlled clinical trials comparing the effectiveness of combined inhaled therapy (SAAC and SABA) to SABA treatment alone to prevent hospitalisations in adults with acute asthma in the emergency department. Two independent review authors assessed studies for inclusion using pre-determined criteria. DATA COLLECTION AND ANALYSIS: For dichotomous outcomes, we calculated individual and pooled statistics as risk ratios (RR) or odds ratios (OR) with 95% confidence intervals (CI) using a random-effects model and reporting heterogeneity (I²). For continuous outcomes, we reported individual trial results using mean differences (MD) and pooled results as weighted mean differences (WMD) or standardised mean differences (SMD) with 95% CIs using a random-effects model. MAIN RESULTS: We included 23 studies that involved a total of 2724 enrolled participants. Most studies were rated at unclear or high risk of bias.Overall, participants receiving combination inhaled therapy were less likely to be hospitalised (RR 0.72, 95% CI 0.59 to 0.87; participants = 2120; studies = 16; I² = 12%; moderate quality of evidence). An estimated 65 fewer patients per 1000 would require hospitalisation after receiving combination therapy (95% 30 to 95), compared to 231 per 1000 patients receiving SABA alone. Although combination inhaled therapy was more effective than SABA treatment alone in reducing hospitalisation in participants with severe asthma exacerbations, this was not found for participants with mild or moderate exacerbations (test for difference between subgroups P = 0.02).Participants receiving combination therapy were more likely to experience improved forced expiratory volume in one second (FEV1) (MD 0.25 L, 95% CI 0.02 to 0.48; participants = 687; studies = 6; I² = 70%; low quality of evidence), peak expiratory flow (PEF) (MD 36.58 L/min, 95% CI 23.07 to 50.09; participants = 1056; studies = 12; I² = 25%; very low quality of evidence), increased percent change in PEF from baseline (MD 24.88, 95% CI 14.83 to 34.93; participants = 551; studies = 7; I² = 23%; moderate quality of evidence), and were less likely to return to the ED for additional care (RR 0.80, 95% CI 0.66 to 0.98; participants = 1180; studies = 5; I² = 0%; moderate quality of evidence) than participants receiving SABA alone.Participants receiving combination inhaled therapy were more likely to experience adverse events than those treated with SABA agents alone (OR 2.03, 95% CI 1.28 to 3.20; participants = 1392; studies = 11; I² = 14%; moderate quality of evidence). Among patients receiving combination therapy, 103 per 1000 were likely to report adverse events (95% 31 to 195 more) compared to 131 per 1000 patients receiving SABA alone. AUTHORS' CONCLUSIONS: Overall, combination inhaled therapy with SAAC and SABA reduced hospitalisation and improved pulmonary function in adults presenting to the ED with acute asthma. In particular, combination inhaled therapy was more effective in preventing hospitalisation in adults with severe asthma exacerbations who are at increased risk of hospitalisation, compared to those with mild-moderate exacerbations, who were at a lower risk to be hospitalised. A single dose of combination therapy and multiple doses both showed reductions in the risk of hospitalisation among adults with acute asthma. However, adults receiving combination therapy were more likely to experience adverse events, such as tremor, agitation, and palpitations, compared to patients receiving SABA alone.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico
Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Antagonistas Colinérgicos/uso terapêutico
[Mh] Termos MeSH secundário: Albuterol/uso terapêutico
Atropina/uso terapêutico
Quimioterapia Combinada
Volume Expiratório Forçado/efeitos dos fármacos
Seres Humanos
Ipratrópio/uso terapêutico
Levalbuterol/uso terapêutico
Metaproterenol/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Derivados da Escopolamina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Anti-Asthmatic Agents); 0 (Cholinergic Antagonists); 0 (Scopolamine Derivatives); 53QOG569E0 (Metaproterenol); 7C0697DR9I (Atropine); 8G15T83E6I (oxitropium); EDN2NBH5SS (Levalbuterol); GR88G0I6UL (Ipratropium); QF8SVZ843E (Albuterol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD001284.pub2


  7 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27920517
[Au] Autor:Tamura T; Satoh H
[Ad] Endereço:Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Ibaraki, Japan.
[Ti] Título:Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone.
[So] Source:Int J Chron Obstruct Pulmon Dis;11:2909-2911, 2016.
[Is] ISSN:1178-2005
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Mh] Termos MeSH primário: Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Brometo de Tiotrópio
[Mh] Termos MeSH secundário: Fluticasona
Seres Humanos
Xinafoato de Salmeterol
Derivados da Escopolamina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Scopolamine Derivatives); 6EW8Q962A5 (Salmeterol Xinafoate); CUT2W21N7U (Fluticasone); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161207
[St] Status:MEDLINE


  8 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26784496
[Au] Autor:Maselli DJ; Peters JI
[Ti] Título:ACP Journal Club. Review: In COPD, tiotropium improves lung function and reduces adverse events compared with ipratropium bromide.
[So] Source:Ann Intern Med;164(2):JC6, 2016 Jan 19.
[Is] ISSN:1539-3704
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Broncodilatadores/uso terapêutico
Ipratrópio/uso terapêutico
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Derivados da Escopolamina/uso terapêutico
Brometo de Tiotrópio/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:COMMENT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bronchodilator Agents); 0 (Scopolamine Derivatives); GR88G0I6UL (Ipratropium); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:160120
[Lr] Data última revisão:
160120
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160120
[St] Status:MEDLINE
[do] DOI:10.7326/ACPJC-2016-164-2-006


  9 / 1967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26718854
[Au] Autor:Samuelsen C; Bateman ED; Pavord I; Lloyd A; Baldwin M; Esser D
[Ad] Endereço:Boehringer Ingelheim, Asker, Norway.
[Ti] Título:Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting ß-Agonists".
[So] Source:Appl Health Econ Health Policy;14(1):117-8, 2016 Feb.
[Is] ISSN:1179-1896
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Mh] Termos MeSH primário: Agonistas Adrenérgicos beta/administração & dosagem
Asma/tratamento farmacológico
Broncodilatadores/economia
Análise Custo-Benefício
Derivados da Escopolamina/economia
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:COMMENT; LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Bronchodilator Agents); 0 (Scopolamine Derivatives)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160213
[Lr] Data última revisão:
160213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160101
[St] Status:MEDLINE
[do] DOI:10.1007/s40258-015-0215-0


  10 / 1967 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:26767288
[Au] Autor:Jiang YB; Gou Y; Yuan MH; Ma YY; Zhou J; Wu PE
[Ti] Título:[HPLC Fingerprint of Anisodus tanguticus Root].
[So] Source:Zhong Yao Cai;38(5):957-61, 2015 May.
[Is] ISSN:1001-4454
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To establish an HPLC fingerprint of Anisodus tanguticus root for its quality control. METHODS: The analysis was carried out on a Ultimate AQ C18 (250 mm x 4.6 mm, 5 µm) column with the gradient elution of acetonitrile and KH2PO4 buffer soution, whose pH was adjusted to 3.0 with phosphoric acid. The flow rate, column temperature, detection wavelength and injection volume was 1.0 mL/min, 30 degrees C, 210 nm and 10 µL separately. The similarity evaluation and principal component analysis were used to analyze HPLC fingerprint of Anisodus tanguticus root. RESULTS: HPLC fingerprint of Anisodus tanguticus root was established with 15 common peaks by determining 18 batches of Anisodus tanguticus root samples. Four characteristic peaks, anisodine, scopolamine, anisodamine and anisodamine, were confirmed by comparing their retention time and UV spectrum with standard reference substances. The simiarities of 18 batches of Anisodus tanguticus root were between -0.891 and 0.987. Comprehensive evaluation scores of 18 batches of Anisodus tanguticus root were between -0.85 and 0.89 by principal component analysis. CONCLUSION: The established HPLC fingerprint has good precision, repeatability and stability, which can provide more comprehensive information for identification and quality control of Anisodus tanguticus root.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/química
Compostos Fitoquímicos/análise
Raízes de Plantas/química
Solanaceae/química
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Análise de Componente Principal
Controle de Qualidade
Derivados da Escopolamina
Hidrobrometo de Escopolamina
Alcaloides de Solanáceas
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (Phytochemicals); 0 (Scopolamine Derivatives); 0 (Solanaceous Alkaloids); 01343Q8EL8 (anisodamine); 451IFR0GXB (Scopolamine Hydrobromide); Z75256J75J (anisodine)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:160115
[Lr] Data última revisão:
160115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160116
[St] Status:MEDLINE



página 1 de 197 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde